A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
AstraZeneca
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center